Receptor- and reactive intermediate-mediated mechanisms of teratogenesis

Peter G Wells1, Crystal J J Lee, Gordon P McCallum

  • 1Division of Biomolecular Sciences, University of Toronto, Toronto, Ontario, Canada. pg.wells@utoronto.ca

Insights

Environmental chemicals and drugs can cause fetal development issues, leading to birth defects or later health problems. The fetus is highly susceptible to these teratogens due to rapid cell division and unique biochemical pathways.

Area of Science:

  • Toxicology
  • Developmental Biology
  • Environmental Health

Background:

  • Drugs and environmental chemicals pose risks to fetal development, causing birth defects and long-term health issues.
  • The fetus is uniquely vulnerable to teratogens due to rapid cell division and distinct biochemical processes.
  • Teratogenesis can manifest as immediate birth defects or delayed functional abnormalities, including neurodevelopmental deficits, metabolic diseases, and cancer.

Purpose of the Study:

  • To elucidate the mechanisms by which xenobiotics induce teratogenesis.
  • To differentiate between receptor-mediated and reactive intermediate-mediated pathways of teratogenesis.
  • To highlight the susceptibility of the fetus to teratogenic agents at low exposure levels.

Main Methods:

  • Review of existing literature on teratogenesis mechanisms.
  • Analysis of animal models and in vitro systems for studying developmental toxicity.
  • Examination of specific pathways including receptor-mediated (e.g., AHR) and reactive intermediate-mediated processes.

Main Results:

  • Teratogenesis involves either receptor-mediated processes (e.g., dioxin-AHR interaction) or reactive intermediate-mediated processes.
  • Reactive intermediates generated by fetal enzymes (CYPs, PHSs) can cause developmental anomalies through covalent binding or oxidative stress.
  • The balance of bioactivation, detoxification, and repair pathways dictates the teratogenicity of reactive intermediates.

Conclusions:

  • Understanding teratogenic mechanisms is crucial for preventing birth defects and postnatal functional deficits.
  • Fetal susceptibility to teratogens is influenced by developmental stage and specific metabolic pathways.
  • Further research into xenobiotic interactions and fetal defense mechanisms is warranted.

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Bioactivation and Tissue Toxicity01:25

Bioactivation and Tissue Toxicity

Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Toxic Reactions: Overview01:26

Toxic Reactions: Overview

When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...